Study identifies critical contributors of pediatric acute lymphoblastic leukemia

Results of one study indicate that the risk for developing pediatric acute lymphoblastic leukemia increased the longer a baby was fed formula and the longer solid foods were delayed.

"For every month that a child was fed formula, taking into account other feeding practices, we found that the risk for this type of cancer was higher," said Jeremy Schraw, a graduate student at The University of Texas at Austin, who presented the findings of an epidemiological study at the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research, held here Oct. 16-19, 2012. "If a baby is fed only formula, he or she will not be getting any immune factors from the mother, which could be leading to this greater risk."

Schraw and colleagues surveyed 284 controls and 142 children from the Texas Children's Cancer Center and the National Children's Study in Houston, San Antonio and Austin, Texas, who had been diagnosed with acute lymphoblastic leukemia (ALL).

Compared with controls, children diagnosed with ALL started solid foods significantly later, more of their mothers smoked during pregnancy and they had a longer duration of formula feeding.

Researchers found that the risk for developing ALL increased by 16 percent for every month of formula feeding. In addition, for each month the introduction of solid foods was delayed, the risk increased by 14 percent.

"One explanation for this co-risk may be that it's the same effect being picked up twice," said Schraw. "Children being given solid foods later may be receiving formula longer."

Future research should address the factors influencing prolonged formula feeding and delay in solid food introduction, according to the researchers.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Northwestern Medicine scientists identify targeted molecular therapy that halts childhood leukemia